### Phase 1

**Sonrotoclax**
- B-cell malignancies
- AML/MDS
- MM (11;14)

**BG-16673**
- BTK CDAC
- B-cell malignancies

**BG-21447**
- Next gen BCL2i
- B-cell malignancies

**Tislelizumab**
- Anti PD1
- SubQ formulation

**Ociperlimab**
- Anti TIGIT
- Dose finding
- R/R DLBCL

**BG-15025 / 26808**
- HPK1i
- 15025 and 26808 - Solid tumors

**BG-30813**
- DKG1i
- Solid tumors

**BG-A3055**
- Anti CCR8
- Solid tumors

**BG-24714**
- SMAC mimetic
- Solid tumors

**BG-10188**
- PI3Kδi
- Solid tumors

**BG-43935**
- CDK4i
- BC & Solid tumors

**BG-68501**
- CDK2i
- Solid tumors

**BG-C9074**
- B7H4 ADC
- Solid tumors

**Zanidatamab**
- Anti HER2 BsAb
- 1L mBC/GC

**Xaluritamig**
- Anti STEAP1 x CD3
- mCRC

---

### Phase 2

**Zanubrutinib**
- BTKi
- B-cell lymphoma
- CD79B R/R DLBCL
- Lupus nephritis

**BG-16673**
- BTK CDAC
- R/R MCL, R/R CLL

**Sonrotoclax**
- BCL2i
- R/R MCL
- R/R CLL
- R/R WM

**Blincyto**
- Anti CD3 x CD19
- Pediatric RR BP-ALL (initiation activities)

**Surzebiclimab**
- Anti TIM3
- 1L HNSCC

**LBL-007**
- Anti LAG3
- MSS-CRC
- 1L ESCC

**BGB-A445**
- Anti OX40
- Melanoma, RCC, UC

**Umbrella Studies**
- IO Combos
  - 1L NSCLC
  - 2L NSCLC
  - Neoadj NSCLC
  - 1L HNSCC

**Zanidatamab**
- Anti HER2 BsAb
  - HER2+ 2L BTC

**Tarlatamab**
- Anti DLL3 x CD3
  - 3L SCLC (initiation activities)

---

### Phase 3

**Zanubrutinib**
- BTKi
- TN MCL
- R/R MCL, R/R FL
- pMM

**Sonrotoclax**
- BCL2i
- TN CLL

**Tislelizumab**
- Anti PD1
  - 1L ES-SCLC (CN)
  - 1L GC/GEJC (US, EU)
  - 1L ESCC (US, EU, JP)
  - 2L ESCC (JP)

**Pamiparib**
- PARPi
- 2L MTx gBRCAm PSOC

**Ociperlimab**
- Anti TIGIT
- 1L NSCLC PD1i-high

**Zanidatamab**
- Anti HER2 BsAb
  - 1L HER2+ GEA

**Tarlatamab**
- Anti DLL3 x CD3
  - 2L SCLC
  - 1L ES-SCLC (initiation activities)
  - LS-SCLC (initiation activities)

---

### Registration

**Zanubrutinib**
- BTKi
- TN CLL/SSL (JP)
- R/R CLL/SSL (JP)
- R/R FL (CN)
- TN R/R WM (JP)

**Tislelizumab**
- Anti PD1
  - 1L ES-SCLC (CN)
  - 1L GC/GEJC (US, EU)
  - 1L ESCC (US, EU, JP)
  - 2L ESCC (JP)

---

### Approved*

**Zanubrutinib**
- BTKi
- TN CLL/SSL (US, EU, CN, Others)
- R/R CLL/SSL (US, EU, Others)
- R/R FL (CN)
- R/R MCL (US, CN, Others)
- R/R WM (US, EU, Others)

**Tislelizumab**
- Anti PD1
  - 1L Non-sq. NSCLC (EU, CN)
  - 1L Sq. NSCLC (EU, CN)
  - 2/3L NSCLC (CN)
  - 1L GC/GEJC (CN)
  - 1L HCC (CN)
  - 2/3L HCC (CN)
  - 1L ESCC (CN)
  - 2L ESCC (US, EU, CN)
  - 2L UBC (CN)
  - 1L NPC (CN)
  - 2L MSI-H/dMMR (CN)
  - R/R chL (CN)

**Pamiparib**
- PARPi
  - 2L gBRCAm OC (CN)

---

### Heme

**Goserelin Microspheres**
- GnRH
  - Prostate cancer (CN)
  - Breast cancer (CN)

---

### Solid tumors

**Sonrotoclax**
- BCL2i
- B-cell lymphoma
- CD79B R/R DLBCL
- Lupus nephritis

**BG-16673**
- BTK CDAC
- R/R MCL, R/R CLL

**Sonrotoclax**
- BCL2i
- R/R MCL
- R/R CLL
- R/R WM

**Blincyto**
- Anti CD3 x CD19
- Pediatric RR BP-ALL (initiation activities)

**Surzebiclimab**
- Anti TIM3
- 1L HNSCC

**LBL-007**
- Anti LAG3
- MSS-CRC
- 1L ESCC

**BGB-A445**
- Anti OX40
- Melanoma, RCC, UC

**Umbrella Studies**
- IO Combos
  - 1L NSCLC
  - 2L NSCLC
  - Neoadj NSCLC
  - 1L HNSCC

**Zanidatamab**
- Anti HER2 BsAb
  - HER2+ 2L BTC

**Tarlatamab**
- Anti DLL3 x CD3
  - 3L SCLC (initiation activities)

---

### Non-Oncology

**Registration includes select accepted submissions**
* Primary endpoint met; CN = China

1. Ensem collaboration, BeiGene has global rights
2. DualityBio collaboration, BeiGene has global rights
3. Zymeworks/Jazz collaboration, BeiGene has APAC/ex Japan, AU, NZ commercial rights
4. Amgen collaboration, BeiGene has China commercial rights and tiered mid single digit royalties on net sales outside of China. "Initiation activities" refers to clinical activities, approval is obtained to initiate the study in China.
5. Leads Biobads collaboration, BeiGene has ex-China commercial rights
6. Luye collaboration, BeiGene has exclusive Mainland China rights to research, development, manufacture, and commercialization for LY01005

*For a full list of our commercial products, including in-licensed products, please refer to our most recent 10-K filing

**Updated May 2024**